ProCE Banner Activity

Phase II ATEZO-BRAIN: Updated Results With Atezolizumab + Carboplatin/Pemetrexed in Advanced Nonsquamous NSCLC With Untreated Brain Metastases

Slideset Download
Conference Coverage
Atezolizumab plus chemotherapy showed favorable safety and promising clinical activity in patients with advanced nonsquamous NSCLC and untreated brain metastases, with a 2-year OS rate of 27.5%.

Released: June 16, 2022

Expiration: June 15, 2023

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

BMS

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation

Seagen and Genmab